Examkin

Question

Difficulty: MediumMonitoring and Treatment Evaluation

On hospital day 6, a 62-year-old woman admitted to the intensive care unit for a massive pulmonary embolism is evaluated for new-onset right leg swelling and pain. She has been continuously managed with an intravenous unfractionated heparin infusion since admission. Laboratory studies from day 1 showed a platelet count of 240,000/μL240,000/\mu L. Today's routine morning laboratory results reveal a platelet count of 90,000/μL90,000/\mu L and an activated partial thromboplastin time (aPTT) of 45 seconds (institutional therapeutic range: 60-80 seconds). A lower extremity venous duplex ultrasound is performed and demonstrates a new, completely occlusive thrombus in the right femoral vein. Which of the following is the most appropriate next step in the management of this patient's anticoagulation therapy?

  1. A
    Increase the infusion rate of unfractionated heparin
  2. B
    Discontinue the unfractionated heparin infusion and transition to subcutaneous enoxaparin
  3. Discontinue the unfractionated heparin infusion and initiate intravenous argatrobanAnswer
  4. D
    Continue the current unfractionated heparin infusion and initiate oral warfarin
  5. E
    Administer a pooled platelet transfusion and continue the current heparin infusion

Answer

The correct answer is to discontinue the unfractionated heparin infusion and initiate intravenous argatroban.
The correct management of highly suspected or confirmed Heparin-Induced Thrombocytopenia (HIT) requires the immediate cessation of all heparin products and the initiation of a non-heparin anticoagulant. This patient presents with a classic HIT presentation: a platelet count drop of greater than 50%, occurring 5 to 10 days after heparin initiation, accompanied by a new thrombotic event (a right femoral deep vein thrombosis). Even though her aPTT is subtherapeutic, the new thrombosis is paradoxically driven by HIT antibodies (IgG directed against heparin-platelet factor 4 complexes). These antibodies activate platelets and cause a highly prothrombotic state. Direct thrombin inhibitors, such as argatroban or bivalirudin, are the drugs of choice for anticoagulation in this setting to prevent further thrombosis while allowing platelet counts to recover.

Step-by-Step Solution

1
Evaluate the patient's new-onset symptoms and laboratory changes in the context of her current pharmacotherapy.
The patient experienced a greater than 50% drop in platelets (from 240,000/μL240,000/\mu L to 90,000/μL90,000/\mu L) and developed a new thrombosis (femoral DVT) on day 6 of intravenous heparin therapy.
Monitoring for adverse effects of high-risk medications is a critical component of treatment evaluation.
2
Calculate the clinical probability for Heparin-Induced Thrombocytopenia (HIT) using the 4T score.
The patient scores highly: Thrombocytopenia >50%, Timing is 5-10 days, Thrombosis is present, and there is no obvious oTher cause.
A high 4T score necessitates immediate clinical intervention prior to the return of confirmatory laboratory testing (e.g., serotonin release assay).
3
Determine the appropriate treatment modification to halt the adverse reaction and manage the underlying condition.
Discontinue all heparin exposure immediately and begin a direct thrombin inhibitor (such as argatroban or bivalirudin) or a factor Xa inhibitor.
Continued heparin exposure fuels the antibody-mediated platelet activation, leading to severe, life-threatening hypercoagulability.

Key Concept

Heparin-Induced Thrombocytopenia (HIT) Diagnosis and Management
Estimated Time:1m 30s
Rate this question

Topics

Monitoring and Treatment Evaluation

More questions from this topic